Status:
TERMINATED
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Lead Sponsor:
Janssen Biotech, Inc.
Conditions:
Crohn's Disease
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection. ...
Detailed Description
The purpose of this study is to assess the effects of REMICADE (infliximab) in preventing relapse of Crohn's disease after surgical resection. Patients will be assigned to a group that will initially ...
Eligibility Criteria
Inclusion
- Have a documented diagnosis of CD confirmed by endoscopic, histologic and/or radiologic studies prior to resection or by tissue obtained at resection
- Have undergone an ileocolonic surgical resection
- Patients must also be at an increased risk of recurrence of active CD
- Patients must not have previously discontinued infliximab as a result of tolerability issues or they must be naive to treatment with infliximab. Provided patients meet the above criteria pertaining to infliximab, they are eligible to enroll if they received prior treatment with adalimumab and/or certolizumab
- Patients must undergo screening for HBV
- Baseline CDAI \< 200
- Have adequate blood and liver test values
Exclusion
- Have a history of latent or active granulomatous infection, including histoplasmosis or coccidioidomycosis, prior to screening
- Have a chest radiograph within 3 months prior to the first infusion of study agent that shows a clinically significant abnormality, such as a malignancy or infection, or any abnormalities suggestive of TB
- Have macroscopically active CD which was not resected at the time of surgery
- Do not meet the criteria for being at an increased risk of postoperative recurrence of active CD as outlined in the inclusion criteria
- Have evidence of an active infection at the time of randomization or have had a serious infection not related to CD (e.g., hepatitis, pneumonia, or pyelonephritis), within 6 months prior to screening
- Have or have had an opportunistic infection (e.g., herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening
- Have any known malignancy or history of malignancy within the 5-year period prior to screening (with the exception of squamous or basal cell carcinoma of the skin that has been completely excised without evidence of recurrence)
- Have any condition that, in the opinion of the investigator, would compromise the well-being of the patient or the study or prevent the patient from meeting or performing study requirements.
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
297 Patients enrolled
Trial Details
Trial ID
NCT01190839
Start Date
November 1 2010
End Date
December 1 2014
Last Update
February 4 2016
Active Locations (142)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
La Jolla, California, United States
3
Orange, California, United States
4
Redwood City, California, United States